Home > Industries > Health Care > Leading company profile
Plunkett Research Online: Takeda Pharmaceutical Company Limited

TAKEDA PHARMACEUTICAL COMPANY LIMITED (TAK:NYS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geograp.....
Takeda Pharmaceutical Company Limited
Ticker: TAK
Exchange: NYS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 81 33278-2111
Fax: 81 33278-2000
Address: 1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo, 103-8668 Japan

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals Discovery & Development
Over-the-Counter Drugs
Vitamins
Research and Development
Biopharmaceuticals
Plasma-based Therapies
Vaccines
Contacts
Description
Christophe WeberCEO/Director/Other Corporate Officer/President
Costa SaroukosCFO/Director
 See More
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geograp.....See More See More

Auditor: KPMG AZSA LLC
Legal Advisor:
Financial Details Compare to Industry Averages Build Custom Table Compare Companies
$USD, In whole numbers,
except marked * or %		202320222021202020192018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Adcetris
Cabozantinib
Ninlaro
Takhzyro
Vonvendi
Entyvio
Alofisel
Vonoprazan
NameTitleSalary (JPY)Bonus (JPY)
Costa SaroukosCFO/Director
Christophe WeberCEO/Director/Other Corporate Officer/President
Andrew PlumpDirector/President, Divisional
Masato Iwasaki,Former Director/Former Other Corporate Officer
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: